Biohaven Pharma (BHVN) and Pfizer (PFE) announce strategic collaboration for the global commercialization of NURTEC ODT outside the United States

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. NVDA
7. PRIM
8. META
9. SPY
10. SPCX

Go back to Biohaven Pharma (BHVN) and Pfizer (PFE) announce strategic collaboration for the global commercialization of NURTEC ODT outside the United States

Biohaven (BHVN) Defended at William Blair

November 9, 2021 11:58 AM EST

William Blair analyst Tim Lugo is out defending Biohaven Pharmaceutical Holding (NYSE: BHVN) on weakness after the company agreed to a strategic deal with Pfizer (NYSE: PFE) versus an outright takeover.

The analyst commented, "We view Nurtec ODT as the... More

Biohaven Pharma (BHVN) Announces Strategic Collaboration with Pfizer (PFE) for Commercialization of Rimegepant Outside the US

November 9, 2021 7:48 AM EST

(Updated - November 9, 2021 7:51 AM EST)

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec® ODT in the U.S., and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. An application for the approval of rimegepant is currently under review by the European Medicines Agency and several additional regulatory... More

Biohaven Pharma (BHVN) Halted, News Pending

November 9, 2021 7:24 AM EST

Biohaven Pharma (NYSE: BHVN) Halted, News Pending

... More